Highlights

  • Dimerix (ASX:DXB) shares advanced 6.25% to $0.26 at the time of writing on 17 July 2026, outperforming the S&P/ASX 200 Health Care index (XHJ), which gained 0.77% on the session.
  • The company has acquired DMX-652, a Phase 2-ready USP30 inhibitor targeting acute kidney injury (AKI), from UK-based Mission Therapeutics, with an upfront payment of US$5 million and milestone payments of up to US$287 million.
  • DMX-652 carries an open US Investigational New Drug (IND) application with FDA approval to proceed to a Phase 2 clinical trial, and comes with sufficient GMP drug product for that trial.
  • Dimerix confirms it is funded through to completion of the Phase 3 ACTION3 trial in DMX-200 and initiation of the DMX-652 Phase 2 trial, supported by existing cash, an Everest Medicines payment of approximately AU$14 million, and a AU$10 million loan facility.

Dimerix Limited (ASX:DXB) is among the session's notable movers on 17 July 2026, with shares advancing 6.25% to $0.26 at the time of writing — a gain that bucks the modest positive drift in the broader S&P/ASX 200 Health Care index (XHJ), which is up 0.77% on the day. The catalyst is a pipeline expansion announcement: Dimerix has acquired DMX-652, a Phase 2-ready drug candidate targeting acute kidney injury (AKI), from Mission Therapeutics Limited. The acquisition broadens the company's renal disease franchise beyond its lead FSGS program and introduces a near-term clinical development catalyst with a differentiated mechanism of action.

DMX-652: Mechanism and Clinical Readiness

DMX-652 is a selective inhibitor of USP30, a mitochondrial deubiquitylase enzyme that slows the removal of damaged mitochondria — a process known as mitophagy. By inhibiting USP30, the compound is designed to support mitochondrial quality control in injured kidney cells, a mechanism that has been implicated in the progression of AKI arising from ischaemia, toxins, or sepsis-related causes. The drug is delivered as a once-daily oral capsule, a formulation that may support broad clinical utility if the mechanism of action proves translatable to multiple indications beyond AKI.

The asset arrives with a Phase 1 clinical trial already completed in 85 healthy volunteers. That study demonstrated tolerability at single doses of up to 200mg per day and multiple doses of up to 100mg per day for 14 days, with no serious adverse events related to the drug and a pharmacokinetic profile described as promising. The open US IND and FDA-approved Phase 2 protocol substantially reduce the regulatory groundwork required before trial initiation, representing a meaningful time advantage relative to an earlier-stage asset.

Phase 2 Target: Cardiac Surgery-Associated AKI

The initial Phase 2 indication is cardiac surgery-associated AKI (CS-AKI), a predictable complication of cardiopulmonary bypass and valve surgery procedures. The proposed trial is a multicentre, double-blind, randomised, placebo-controlled study in approximately 160 patients at high risk of AKI following cardiac surgery. The primary endpoint is AKI incidence at seven days post-surgery. Clinical trial ethics approval and site initiation is expected in the second half of calendar year 2026, with the first patient dosed anticipated in the first half of 2027 and an interim data readout planned during 2027. The CS-AKI patient population — estimated at 100,000–133,000 annually in the United States — may support orphan drug designation, a pathway that could provide five to ten years of post-marketing exclusivity.

Financial Terms and Milestone Structure

Under the acquisition agreement, Dimerix will pay Mission Therapeutics a US$5 million upfront payment within 30 days of signing. The deferred milestone payment structure includes up to US$47 million on achievement of predefined clinical development milestones, US$40 million on product marketing approval, US$25 million on approval in a second indication, and up to US$175 million in sales-based milestones — bringing total potential consideration to US$287 million. Royalty obligations range from 8–10% on global net sales if commercialised by Dimerix, or 2.5–5% if commercialised through a sub-licensee. Patent protection for DMX-652 extends to 2041, and the company has acquired the composition of matter patent family along with the IND, GMP drug product, and relevant manufacturing methodology.

Portfolio Context: DMX-200 and the ACTION3 Trial

The DMX-652 acquisition sits alongside Dimerix's lead program, DMX-200, which is in a fully recruited Phase 3 pivotal trial (ACTION3) for focal segmental glomerulosclerosis (FSGS), a rare kidney disease characterised by scarring of the kidney's filtering units. The Phase 3 trial represents a substantial near-term value event if successful. By advancing a complementary asset into Phase 2 development simultaneously, Dimerix is constructing a two-program renal franchise — one in glomerular disease (FSGS) and one in acute kidney injury — that it frames as a platform for longer-term pipeline development in rare and renal disease.

Funding Position

Dimerix has confirmed it is funded through to completion of the ACTION3 trial and initiation of the DMX-652 Phase 2 study. The funding sources comprise existing cash reserves, approximately AU$14 million in upfront payments to be received from Everest Medicines for rights to Greater China, South Korea, and Southeast Asia, and a AU$10 million binding loan facility available at the company's discretion. The company is also in discussions for up to an additional AU$40 million in non-dilutive funding on substantially similar terms, which management indicates would extend the cash runway beyond the ACTION3 trial and support pipeline development beyond the two current programs.

Market Opportunity

The global market for acute kidney injury treatments is estimated at US$3.5 billion in 2026, with forecasts pointing to approximately US$7.5 billion over the following decade. There are currently no approved therapies for AKI — a gap the company is positioning DMX-652 to address. The Phase 2 trial design, focused on a well-defined patient population in a high-risk surgical setting, is structured to generate clinical data that could inform subsequent indication expansion, including the potential to extend DMX-652's utility across ischaemia-reperfusion injuries in other organ systems.

Conclusion

Dimerix (ASX:DXB) has moved decisively to expand its pipeline with the acquisition of a Phase 2-ready AKI asset, building on its existing FSGS franchise and providing additional near-term clinical catalysts for the market to assess alongside the ACTION3 Phase 3 readout. The share price advance on 17 July 2026 reflects market recognition of the expanded pipeline profile and the strength of the asset's clinical preparation. The funding position, as confirmed by management, supports both programs through key milestones. Investors are encouraged to review the company's ASX disclosures in detail and seek professional advice before making any decisions.